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Abstract
Background Association between chronic obstructive pulmonary disease (COPD) and long-term mortality as well as the 
quality of life (QoL) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) 
is still unclear.
Aim We sought to evaluate the impact of COPD on mortality and QoL of patients with AS undergoing TAVI.
Methods A total of 148 consecutive patients who underwent TAVI were enrolled and stratified by history of COPD.
Results Of 148 patients enrolled, 19 (12.8%) patients had a history of COPD. Patients with COPD were high-risk patients 
with higher prevalence of incomplete revascularization and frailty features. At follow-up of 15.8 months, all-cause mortality 
in patients with COPD was over four times higher than in patients without COPD [17.8% vs. 52.6%; p = 0.002—age/gender-
adjusted OR (95% CI) 4.73 (1.69–13.24)]. On the other hand, in Cox regression model, the only independent predictors 
of all-cause death at long-term follow-up were: incomplete coronary revascularization [HR (95% CI) 5.45 (2.38–12.52); 
p = 0.001], estimated glomerular filtration rate [per 1 ml/min/1.73 m2 increase: 0.96 (0.94–0.98); p = 0.001], and previous 
stroke/transient ischemic attack [2.86 (1.17–7.00); p = 0.021]. Also, the difference in mortality between patients with and 
without COPD was not significant after adjustment for the most of frailty indices. Importantly, groups were comparable in 
terms of QoL at baseline and 12 months.
Conclusion COPD may pose an important factor affecting long-term outcomes of patients with severe AS undergoing TAVI. 
However, its effects might be partially related to coexisting comorbidities and frailty.
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Introduction
Concomitant chronic obstructive pulmonary disease (COPD) 
in patients with severe aortic stenosis (AS) is associated with 
higher morbidity and mortality after surgical aortic valve 
replacement (SAVR) [1, 2]. Furthermore, COPD is consid-
ered as a marker of poor prognosis and is incorporated in 
the contemporary cardiac surgery risk prediction models 
[3, 4]. This results in many elderly patients with severe AS 
and concomitant COPD being denied surgery and sched-
uled for transcatheter aortic valve implantation (TAVI) as a 
lower risk alternative. However, in spite of an improvement 
in outcomes and quality of life (QoL) after TAVI [5–12], 
recently, some studies reported a detrimental effect of COPD 
on outcomes of patients with severe AS undergoing TAVI 
[13–15]. Nevertheless, the impact of COPD on TAVI results 
seems to be still unclear [16, 17]. Also, data on the possible 
associations between COPD, frailty, QoL, and outcomes for 
patients undergoing TAVI are scarce. Thus, we sought to 
evaluate the impact of COPD on long-term outcomes and 
QoL in patients with severe AS undergoing TAVI.
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Methods
A total of 148 consecutive patients with symptomatic 
severe AS who underwent TAVI were included. All the 
patients were considered inoperable or high-risk for con-
ventional SAVR [8]. Baseline characteristics and proce-
dural data were collected prospectively. Frailty indices 
were assessed before TAVI with the Katz index of Inde-
pendence of Activities in Daily Living, elderly mobility 
scale (EMS) score, Canadian Study of Health and Aging 
(CSHA)  scale, 5-meter walking test, dominant hand 
grip strength, and Identification of Seniors at Risk scale 
[18]. Hand grip strength assessment was performed by 
1 physician and it was subjectively distinguished into 
the following: weak, mild and strong. It was performed 
using patient’s dominant hand and patients were asked to 
squeeze dominant hand as tightly as possible (repeated 
twice) [18]. TAVI procedures were performed using 
Edwards Sapien, Edwards Sapien XT, Edwards Sapien 
3 (Edwards Lifesciences), Medtronic CoreValve/Evolut 
R (Medtronic, Inc), JenaValve (JenaValve Technology), 
Lotus (Boston Scientific) and NVT (New Valve Technol-
ogy). The decision on type and size of the valve as well as 
access route was at the discretion of the Heart Team and 
treating physicians. Procedures were performed under gen-
eral or local anesthesia with mild sedation. Clinical end-
points of the study included all-cause mortality at 30 days 
and every 6 months up to maximal available follow-up and 
complications rate up to 12 months. Outcome end points 
were in accordance with Valve Academic Research Con-
sortium definitions (VARC-2) [19]. QoL was assessed with 
the self-reported Polish validated version of the EQ-5D-3L 
questionnaire at baseline and at 12 months after TAVI. The 
EQ-5D-3L is a health-related QoL measure, consisting of 
5 three-level items, representing various aspects of health: 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Respondents can score each domain 
from one (no problems) to three (extreme problems). The 
visual analog scale (VAS) score, which is a part of the 
EQ-5D-3L, was also assessed. For the analysis, patients 
were stratified by history of COPD as patients with and 
without concomitant COPD. The diagnosis of COPD was 
based on the medical history and the results of pulmonary 
function tests [20]. Spirometry was an obligatory part of 
the diagnostic work-up for all patients scheduled for TAVI. 
Standard reference values were used.
Results are presented as number of patients (percentage) 
or median (interquartile range [IQR]) where applicable. 
Continuous variables were compared with Mann–Whitney 
U test. Categorical variables were compared with the Chi 
square test or Fisher’s exact test. Changes in the propor-
tions of patients who reported either “no problems” or 
“some problems”/“extreme problems” on the EQ-5D-3L 
between baseline and follow-up visits were analyzed using 
McNemar’s test. Differences in the VAS score between 
baseline and follow-up assessments were analyzed with 
a Wilcoxon signed-rank test. All comparisons between 
baseline and 12-month measurements were performed 
excluding unpaired results. Survival curves were con-
structed using Kaplan–Meier estimates and compared 
using the log-rank test. Differences in outcomes are pre-
sented as adjusted for age/gender odds ratios (OR) with 
confidence intervals (95% CI). In addition, a multivari-
able Cox proportional hazards model including baseline 
variables (except for frailty indices) was used to identify 
predictors of all-cause mortality at maximal follow-up. 
Forward selection with a probability value for covari-
ates to enter the model was set at the 0.05 level. Then, 
additional Cox regression models adjusted for age/gender 
were constructed to assess associations between COPD, 
frailty and maximal follow-up all-cause mortality. Results 
are presented as hazard ratios (HR) with associated 95% 
CI. A 2-sided p value < 0.05 was considered statistically 
significant. All analyses were performed using SPSS 15.0 
(SPSS, Inc, Chicago, IL, USA).
Results
A total of 148 consecutive patients who underwent TAVI 
were enrolled. Of them, 19 (12.8%) patients had a history of 
COPD. Patients with COPD were high-risk individuals with 
higher prevalence of diabetes mellitus, previous myocardial 
infarction (MI) and percutaneous coronary intervention as 
compared to patients without COPD (Table 1). In addition, 
patients with COPD were more likely to have incomplete 
coronary revascularization before TAVI. The prevalence 
of frailty features as assessed with EMS, CSHA, and Katz 
indices was numerically higher in patients with than without 
COPD. The grip strength in patients with COPD was lower 
than in patients without COPD. However, no difference 
in the prevalence of ‘weak’ category between groups was 
observed (Table 2). Despite some dissimilarities in baseline 
risk profile, there were no differences regarding procedural 
technique and echocardiographic outcomes of TAVI between 
patients with and without COPD (Table 3).
The median length of hospital stay was comparable 
between groups [COPD (−) vs. COPD (+): 10.0 (8.0–13.0) 
vs. 9.5 (7.0–12.0) days; p = 0.50]. No difference in the rate 
of bleeding [32.6% vs. 36.8%; p = 0.71, age/gender-adjusted 
OR (95% CI) 1.23 (0.44–3.39)] as well as blood transfusion 
[29.5% vs. 31.6%; p = 0.85—age/gender-adjusted OR (95% 
CI) 1.12 (0.39–3.23)] during hospital stay was observed. 
Similarly, the rate of grade 3 acute kidney injury (AKI) was 
comparable between groups [5.4% vs. 5.4%; p = 1.00—age/
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gender-adjusted OR (95% CI) 0.87 (0.10–7.96)]. At 30 days, 
no difference in all-cause mortality was observed [7.8% vs. 
10.5%; p = 0.65—age/gender-adjusted OR (95% CI) 1.37 
(0.27–6.90)]. However, at 12 months all-cause mortality in 
patients with COPD was over 4 times higher than in patients 
without COPD [11.6% vs. 36.8%; p = 0.010—age/gender-
adjusted OR (95% CI) 4.19 (1.34–13.09)]. This difference 
in mortality was maintained during the median follow-up of 
15.8 (6.4–33.1) months [17.8% vs. 52.6%; p = 0.002—age/
gender-adjusted OR (95% CI) 4.73 (1.69–13.24)]—Fig. 1. 
On the other hand, the difference in mortality between 
patients with and without COPD was not significant after 
adjustment for most of the frailty indices (Table 4). In addi-
tion, in Cox regression model, COPD was not identified as 
an independent predictor of long-term all-cause mortality. 
The only independent predictors were: incomplete coro-
nary revascularization [HR (95% CI) 5.45 (2.38–12.52); 
p = 0.001], estimated glomerular filtration rate [HR (95% CI) 
per 1 ml/min/1.73 m2 increase: 0.96 (0.94–0.98); p = 0.001], 
and previous stroke/transient ischemic attack [HR (95% CI) 
2.86 (1.17–7.00); p = 0.021]. In addition, a trend towards 
higher risk of MI [1.6% vs. 10.5%; p = 0.08—age/gender-
adjusted OR (95% CI) 8.52 (0.94–77.55)], cerebrovascular 
accidents [5.4% vs. 15.8%; p = 0.12—age/gender-adjusted 
OR (95% CI) 2.77 (0.63–12.28)], and new onset of atrial 
fibrillation [5.4% vs. 15.8%; p = 0.012—age/gender-
adjusted OR (95% CI) 2.45 (0.53–11.32)] at 12 months was 
noted in patients with COPD. New permanent pacemaker 
Table 1  Baseline characteristics and echocardiographic data
Variable All patients (n = 148) Chronic obstructive pulmonary 
disease
p value
Absent (n = 129) Present (n = 19)
Age, median (IQR) [years] 82.0 (77.0–85.0) 82.0 (78.0–85.0) 78.0 (75.5–83.5) 0.26
Age ≥ 80 years 92 (62.2%) 83 (64.3%) 9 (47.4%) 0.15
Men 56 (37.8%) 46 (35.7%) 10 (52.6%) 0.15
Body mass index, median (IQR) [kg/m2] 27.2 (25.2–30.6) 27.3 (25.3–30.2) 28.1 (25.8–33.8) 0.39
Estimated glomerular filtration rate, median (IQR) [ml/min/1.73 m2] 56.5 (40.0–72.0) 54.0 (39.0–72.0) 66.0 (45.0–80.0) 0.19
New York Heart Association class 0.24
 I 0 (0.0%) 0 (0.0%) 0 (0.0%)
 II 41 (27.7%) 36 (27.9%) 5 (26.3%)
 III 97 (65.5%) 86 (66.7%) 11 (57.9%)
 IV 10 (6.8%) 7 (5.4%) 3 (15.8%)
Arterial hypertension 139 (93.9%) 120 (93.0%) 19 (100.0%) 0.61
Diabetes mellitus 48 (32.4%) 38 (29.5%) 10 (52.6%) 0.044
Atrial fibrillation 52 (35.1%) 44 (34.1%) 8 (42.1%) 0.50
Previous myocardial infarction 48 (32.4%) 38 (29.5%) 10 (52.6%) 0.044
Previous percutaneous coronary intervention 43 (29.1%) 33 (25.6%) 10 (52.6%) 0.015
Previous coronary artery bypass grafting 28 (18.9%) 26 (20.2%) 2 (10.5%) 0.53
Chronic total occlusion 14 (9.5%) 8 (6.2%) 6 (31.6%) 0.003
Incomplete revascularization 22 (14.9%) 15 (11.6%) 7 (36.8%) 0.010
Previous stroke/transient ischemic attack 17 (11.5%) 13 (10.1%) 4 (21.1%) 0.24
Pacemaker 17 (11.5%) 17 (13.2%) 0 (0.0%) 0.13
Logistic Euroscore I, median (IQR) [%] 14.5 (10.0–22.7) 14.0 (10.0–22.0) 15.0 (13.4–23.5) 0.10
The Society of Thoracic Surgeons score, median (IQR) [%] 6.2 (4.0-17.3) 7.0 (4.0–17.0) 5.5 (3.8–30.0) 0.65
Maximal transvalvular gradient, median (IQR) [mmHg] 86.0 (69.0–103.0) 87.0 (70.0–104.0) 80.0 (71.0–90.5) 0.21
Mean transvalvular gradient, median (IQR) [mmHg] 50.0 (42.0–63.0) 50.0 (42.0–64.5) 47.0 (42.5–53.0) 0.37
Aortic valve area, median (IQR)  [cm2] 0.7 (0.6–0.8) 0.7 (0.5–0.8) 0.7 (0.6–1.0) 0.09
Left ventricle ejection fraction, median (IQR) [%] 60.0 (50.0–65.0) 60.0 (50.0–65.0) 60.0 (49.5–65.0) 0.57
Aortic regurgitation 0.034
 0 48 (32.4%) 46 (35.7%) 2 (10.5%)
 1 75 (50.7%) 62 (48.1%) 13 (68.4%)
 2 20 (13.5%) 18 (14.0%) 2 (10.5%)
 3 5 (3.4%) 3 (2.3%) 2 (10.5%)
Systolic pulmonary artery pressure ≥ 46 mmHg 65 (43.9%) 54 (41.9%) 11 (57.9%) 0.19
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implantation was required in 17.1% of patients without 
COPD and 10.5% of patients with COPD [p = 0.74—age/
gender-adjusted OR (95% CI) 0.60 (0.13–2.80)].
In general, baseline QoL parameters as assessed with the 
EQ-5D-3L were comparable between groups. However, a 
higher rate of reporting either “some problems”/“extreme 
problems” in terms of self-care in patients with COPD as 
compared with those without COPD was observed (Fig. 2). 
An improvement in QoL after 12 months was confirmed for 
both groups for mobility and anxiety/depression compo-
nents of the EQ-5D-3L. On the contrary, an improvement 
in self-care was confirmed only for patients with COPD. 
The median VAS score at baseline [40.0 (30.0–50.0) 
vs. 45.0 (25.0–60.0); p = 0.83] and 12  months [70.0 
(60.0–80.0) vs. 70.0 (60.0–77.5); p = 0.56] was compara-
ble between groups. No difference in change of VAS from 
baseline to 12 months was found [25.0 (15.0–40.0) vs. 25.0 
(10.0–30.0); p = 0.58].
Discussion
The major finding of our study is that COPD had a detri-
mental effect on long-term all-cause mortality in patients 
with severe AS scheduled for TAVI. These results were 
maintained after the adjustment for age and gender, while 
no difference in mortality between patients with and with-
out COPD was observed after adjustment for most of the 
frailty indices. Furthermore, COPD was not identified as 
an independent predictor of long-term all-cause mortality. 
Thus, effects of COPD might be partially related to coex-
isting comorbidities and frailty. Importantly, our findings 
stay in line with the previous studies reporting association 
between COPD and adverse outcomes after TAVI [13–15, 
21, 22]. However, other studies presented contradictory 
results suggesting no influence of COPD on mortality 
after TAVI [16, 17]. For instance, in multicenter Cana-
dian experience, the strongest predictor of late mortality 
was COPD followed by chronic kidney disease, chronic 
atrial fibrillation, and frailty [21]. A recent large meta-
analysis [13] has reported negative impact of COPD on 
both short- and long-term all-cause mortality (30 days 
OR 1.43, 95% CI 1.14–1.79; >2 years: HR 1.34, 95% CI 
1.12–1.61). COPD was also associated with increased 
short- and mid-term cardiovascular mortality (30 days 
OR 1.29, 95% CI 1.02–1.64; 1 year: HR 1.09, 95% CI 
1.02–1.17). Furthermore, patients with COPD had 2 times 
higher risk for AKI than patients without COPD. It has 
been suggested that COPD is likely to cause a reduction 
of renal blood flow [23], and that periprocedural impair-
ment of heart function and the occurrence of hypoxemia 
and hypercapnia can lead to deterioration in renal func-
tion [13, 24]. In addition, COPD has been reported as an 
important predictor of stroke after TAVI [25]. In our study, 
only a trend towards higher risk of MI, new onset atrial 
fibrillation, and cerebrovascular accidents was noted in 
patients with COPD at 12-month follow-up. Numerically 
higher rates of those adverse events may suggest that 
those results could reach statistical significance with a 
large sample. Importantly, paroxysmal atrial fibrillation 
Table 2  Frailty indices in patients with and without chronic obstructive pulmonary disease
Variable Categories All patients
(n = 148)
Chronic obstructive pulmonary 
disease
p value
Absent
(n = 129)
Present
(n = 19)
5-meter walking test (seconds) ≥ 6, frail 21 (14.2%) 17 (13.2%) 4 (21.1%) 0.48
Elderly mobility scale (points) < 10, frail 8 (5.4%) 5 (3.9%) 3 (15.8%) 0.11
10–13 93 (62.8%) 83 (64.3%) 10 (52.6%)
> 13 47 (31.8%) 41 (31.8%) 6 (31.6%)
Canadian Study of Health and Aging scale (points) 1–3 87 (58.8%) 78 (60.5%) 9 (47.4%) 0.06
4 44 (29.7%) 37 (28.7%) 7 (36.8%)
5, frail 3 (2.0%) 1 (0.8%) 2 (10.5%)
6–7, frail 14 (9.5%) 13 (10.1%) 1 (5.3%)
Katz index (points) < 6, frail 19 (12.8%) 14 (10.9%) 5 (26.3%) 0.07
Grip strength (grade) Weak, frail 7 (4.7%) 6 (4.7%) 1 (5.3%) 0.025
Mild 14 (9.5%) 9 (7.0%) 5 (26.3%)
Strong 127 (85.8%) 114 (88.4%) 13 (68.4%)
Identification of Seniors at Risk scale (points) ≥ 2, functional 
decline, frail
53 (35.8%) 46 (35.7%) 7 (36.8%) 0.92
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is quite common among patients with COPD and might 
be related to COPD exacerbation and treatment with theo-
phylline [26, 27]. Also, COPD and coronary artery disease 
share several risk factors such as smoking habit and aging. 
Thus, it is expected that a considerable number of patients 
with COPD scheduled for TAVI also have concomitant 
coronary artery disease. In our study, these patients were 
more likely to have chronic total occlusions and incom-
plete revascularization of coronary arteries before TAVI. 
This result might be related to a higher prevalence of dia-
betes mellitus, previous MI and percutaneous coronary 
intervention in the COPD group. On the other hand, a link 
between COPD and systemic inflammatory response was 
suggested. That way COPD may hasten the progression 
of atherosclerotic disease as well as the destabilization 
of existing atherosclerotic plaques [27]. Interestingly, a 
systemic inflammatory response measured by elevation of 
C-reactive protein, interleukin-6, and interleukin-8 levels 
has been shown to be associated with worse prognosis in 
patients undergoing TAVI [28].
Frailty and sarcopenia have been shown to be a fre-
quent condition in elderly patients and should be consid-
ered when dealing with invasive care in the elderly [18, 
29]. Importantly, both frailty and sarcopenia are common 
among patients with a chronic respiratory disease [30]. 
Also, those were shown to be associated with worse out-
comes of patients with severe AS undergoing TAVI [18, 
29]. In our study, the prevalence of frailty was numerically 
higher in patients with than without COPD and the presence 
of frailty was strongly associated with long-term all-cause 
Table 3  Procedural and echocardiographic data after the procedure
Variable All patients
(n = 148)
Chronic obstructive pulmonary disease p value
Absent
(n = 129)
Present
(n = 19)
Access type 0.84
 Transfemoral 117 (79.1%) 102 (79.1%) 15 (78.9%)
 Transapical 28 (18.9%) 24 (18.6%) 4 (21.1%)
 Transaortic 2 (1.4%) 2 (1.6%) 0 (0.0%)
 Subclavian 1 (0.7%) 1 (0.8%) 0 (0.0%)
Device implanted 0.23
 Corevalve / Evolut R 29 (19.6%) 28 (21.7%) 1 (5.3%)
 Edwards Sapien 95 (64.2%) 83 (64.3%) 12 (63.2%)
 Jena 10 (6.8%) 7 (5.4%) 3 (15.8%)
 Lotus 9 (6.1%) 7 (5.4%) 2 (10.5%)
 NVT 5 (3.4%) 4 (3.1%) 1 (5.3%)
Prosthesis size 0.35
 23 mm 30 (20.3%) 26 (20.2%) 4 (21.1%)
 25 mm 8 (5.4%) 7 (5.4%) 1 (5.3%)
 26 mm 56 (37.8%) 52 (40.3%) 4 (21.1%)
 27 mm 8 (5.4%) 6 (4.7%) 2 (10.5%)
 29 mm 38 (25.7%) 32 (24.8%) 6 (31.6%)
 31 mm 8 (5.4%) 6 (4.7%) 2 (10.5%)
Prosthesis size, median (IQR) [mm] 26.0 (25.0–29.0) 26.0 (25.0–29.0) 27.0 (25.5–29.0) 0.33
Maximal transvalvular gradient, median (IQR) [mmHg] 13.0 (10.0–19.0) 13.0 (10.0–19.0) 16.0 (13.0–21.0) 0.13
Median transvalvular gradient, median (IQR) [mmHg] 7.4 (5.1–10.0) 7.0 (5.0–10.0) 9.0 (6.0–11.0) 0.12
Left ventricle ejection fraction, median (IQR) [%] 48.0 (41.0–55.0) 49.0 (43.0–55.0) 45.0 (32.5–60.0) 0.61
Aortic regurgitation 0.60
 0 84 (56.8%) 71 (55.0%) 13 (68.4%)
 1 55 (37.2%) 50 (38.8%) 5 (26.3%)
 2 7 (4.7%) 6 (4.7%) 1 (5.3%)
 3 2 (1.4%) 2 (1.6%) 0 (0.0%)
Radiation dose, median (IQR) [mGy] 721.0 (632.5–827.5) 713.0 (632.0–823.0) 789.0 (639.5–905.5) 0.13
Contrast medium load, median (IQR) [ml] 75.0 (50.0–137.5) 75.0 (50.0–100.0) 75.0 (50.0–125.0) 0.80
Fluoroscopy time, median (IQR) [min] 13.0 (12.0–15.0) 13.0 (12.0–15.0) 13.0 (12.0–14.0) 0.70
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mortality. On the other hand, the observed difference in 
mortality between patients with and without COPD was 
not significant after correction for frailty indices. However, 
in patients with COPD and severe AS, it may be difficult 
to distinguish the precise contribution of each pathology, 
when progressive dyspnea appears [31]. Also, in inoper-
able patients with severe AS and COPD, it seems crucial 
to define the border between utility and futility, when the 
condition is too far advanced and the risk too high even for 
this less invasive procedure.
Evaluation of QoL seems to be an important index as 
frequently not a reduction in mortality but improvement in 
daily life comfort is most desirable by patients themselves 
[9–11]. Importantly, improvement in QoL after TAVI may 
be higher than observed after SAVR, even with the use 
of minimally-invasive surgical techniques (mini-thoracot-
omy, mini-sternotomy) [11]. However, these benefits in 
terms of improvement in QoL after TAVI may be affected 
by the presence of comorbidities, including COPD. De 
Oliveira et al. [32] suggested that QoL in patients with 
COPD was lower than expected. Also, up to 20% of 
patients with COPD were on antidepressants, which had 
a possible influence on QoL outcomes [32]. Furthermore, 
increasing level of severity of COPD was associated with 
a significant decline in the EQ-5D VAS scores and util-
ity scores [33]. In our study, an improvement in QoL at 
12 months after TAVI was confirmed for patients both 
with and without COPD for mobility and anxiety/depres-
sion components of the EQ-5D-3L. On the contrary, an 
improvement in self-care was confirmed only for patients 
with COPD. No difference in VAS change during follow-
up between groups was reported. This might suggest an 
equal response to TAVI in terms of QoL regardless of 
COPD status.
Several important limitations of the present study 
should be acknowledged. First, the study has all the limi-
tations of a single-center registry. Second, patients were 
not stratified by the severity of COPD. It is probable 
that the relative impact of COPD on outcomes is depend-
ent on disease severity. Third, symptoms control and a 
history of exacerbations, as well as type of treatment, 
were not assessed. Finally, the tools used for QoL and 
frailty assessment were non-disease-specific instruments. 
Prevalence of depression and the use of antidepressants 
in patients with COPD were not evaluated. However, 
despite several limitations, our study represents a com-
plete analysis of consecutive patients without any exclu-
sion criteria and with follow-up data available for all 
patients.
Fig. 1  Kaplan–Meier curves for survival after transcatheter valve 
implantation stratified by chronic obstructive pulmonary disease 
(COPD) status (without COPD solid line; with COPD dotted line)
Table 4  Impact of chronic 
obstructive pulmonary disease 
and frailty indices on maximal 
follow-up all-cause mortality
Variable Age/gender-adjusted HR (95% 
CI)
p value
5-meter walking test ≥ 6 s 14.71 (6.50–33.3) < 0.001
Chronic obstructive pulmonary disease 1.47 (0.66–3.26) 0.34
Elderly mobility scale < 10 points 13.80 (5.34–35.64) < 0.001
Chronic obstructive pulmonary disease 1.41 (0.58–3.42) 0.45
Canadian Study of Health and Aging scale 5–7 points 39.10 (15.85–96.46) < 0.001
Chronic obstructive pulmonary disease 1.82 (0.79–4.18) 0.16
Katz index < 6 points 13.92 (6.29–30.79) < 0.001
Chronic obstructive pulmonary disease 1.10 (0.48–2.56) 0.82
Weak grip strength 28.84 (10.54–78.87) < 0.001
Chronic obstructive pulmonary disease 3.09 (1.37–6.95) 0.006
Identification of Seniors at Risk scale ≥ 2 points 5.25 (2.20–12.55) < 0.001
Chronic obstructive pulmonary disease 2.57 (1.16–5.70) 0.021
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